Astra eyes record merger with drug rival Gilead: report

pharmaceuticals
Credit: Pixabay/CC0 Public Domain

British pharmaceuticals group AstraZeneca has approached US rival Gilead Sciences over a possible record merger, Bloomberg reported, as the pair spearhead treatments for COVID-19.

AstraZeneca informally contacted Gilead last month, Sunday's report said, adding that a combined group would be worth a record-breaking $236 billion when taking into account the companies' closing valuations Friday.

That was trimmed Monday, with AstraZeneca's down 2.14 percent at the start of London trading.

Gilead's antiviral drug remdesivir has been shown to help severely ill coronavirus patients, while AstraZeneca is trialing a COVID-19 vaccine.


Explore further

Gilead shares surge on report of drug's success on COVID-19

© 2020 AFP

Citation: Astra eyes record merger with drug rival Gilead: report (2020, June 8) retrieved 30 November 2020 from https://medicalxpress.com/news/2020-06-astra-eyes-merger-drug-rival.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments